NICE Downs GSK’s Benlysta In Second Lupus Indication On Comparator Grounds
This article was originally published in The Pink Sheet Daily
Executive Summary
In yet another knock-back of GSK’s lupus drug Benlysta in the U.K., NICE said cost and comparator issues were not adequately addressed by the British manufacturer.
You may also be interested in...
Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems
Industry and regulators are showing more interest in implementing adaptive licensing in Europe. Both sides agree that increased trust and transparency could be stepping stones towards this goal.
GSK’s Benlysta Discount Isn’t Big Enough To Avoid NICE Rejection
NICE says GSK did not adequately compare its lupus drug belimumab to Roche’s Mab Thera (rituximab). While the firm and partner Human Genome Sciences did offer data that appeared to show an advantage, the problem is that the positive results were more prevalent in a patient population that did not broadly reflect the make-up of the U.K., NICE said.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.